News

Serpin Pharma Secures $2 Million NCI Grant for Innovative Neuropathy Treatment

Serpin Pharma, a Virginia-based biopharmaceutical company, is proud to announce that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI).

This grant will support the clinical development of SP16-3M, a groundbreaking peptide drug designed to prevent chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients.

Collaborative Clinical Trial

The funding will facilitate a collaborative clinical trial led by Dr. Patrick Dillon at the University of Virginia. The trial aims to evaluate the efficacy of SP16-3M in:

– Protecting nerves from chemotherapy-induced toxicity

– Facilitating nerve repair

– Alleviating pain for breast cancer patients undergoing treatment

Addressing a Critical Need

CIPN is a common and often debilitating side effect of cancer treatment that can significantly impact patients’ quality of life. SP163M represents a potential breakthrough in managing this condition. By preventing neuropathy, SP163M could enable patients to complete their full chemotherapy regimens without dose reductions, potentially improving overall cancer treatment outcomes.

Expert Insights

Dr. Patrick Dillon expressed his enthusiasm for the collaboration: “I am excited about this partnership, as both UVA and Serpin are dedicated to finding solutions for treatment-induced neuropathy in cancer patients.”

Dr. Cohava Gelber, Founder and CEO of Serpin Pharma, also shared her thoughts: “We are thrilled to work with Dr. Dillon and UVA to bring the promise of our groundbreaking drug to breast cancer patients, aiming to prevent their suffering from debilitating pain after chemotherapy.”

Looking Ahead
The NCI award highlights the significant potential of SP163M in addressing a critical unmet need in cancer care. As Serpin Pharma advances its clinical development efforts, breast cancer patients may soon have access to this innovative therapy, enhancing their quality of life during and after chemotherapy.

 

Learn more here.

Recent News

02/05/2025

Project Vital bringing millions in funding to Roanoke-Blacksburg’s life sciences

The Roanoke-Blacksburg region is establishing itself as a biomedical research hub and medical device innovation center. About $5 million from the state could help move that work from labs to markets. Those millions will fund Project Vital: Virginia Innovations and Technology Advancements in Life Sciences. It’s a collaboration among the Roanoke-Blacksburg Innovation Alliance (formerly Verge),

01/31/2025

AGC Pharma Chemicals announces expansion of HPAPI capabilities in Barcelona

AGC Pharma Chemicals, a leading innovator in pharmaceutical manufacturing with over 40 years of expertise in Contract Development Manufacturing Operations (CDMO) for small molecule APIs based in Barcelona (Spain) and Japan, announces a significant expansion of its High Potency Active Pharmaceutical Ingredients (HPAPI) capabilities, enabling seamless scale-up from grams to tons within a single integrated

01/30/2025

OrthoPreserve Receives Both FDA Breakthrough Device Designation and Prestigious TAP Enrollment for Meniscus Implant to Revolutionize Knee Pain Treatment

OrthoPreserve, a company developing orthopedic implant solutions, announced today it has been granted both a Breakthrough Device Designation and Total Product Life Cycle Advisory Program (TAP) enrollment from the U.S. Food & Drug Administration (FDA) for Defender, a meniscus replacement implant. The designation covers the use of the therapeutic medical device to treat patients who